Pulmonx to Participate in Upcoming Investor Conferences
Pulmonx (Nasdaq: LUNG) announced that its management team will participate in two upcoming investor events.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pulmonx (Nasdaq: LUNG) announced that its management team will participate in two upcoming investor events. The company will attend the Wells Fargo Healthcare Conference for 1x1 meetings on Wednesday, September 9 in Boston, MA, and the Lake Street Best Ideas Growth (BIG10) Conference for 1x1 meetings on Thursday, September 10 in New York, NY.
Details
News Market Reaction – LUNG
On Aug 28, the first trading day after this news, LUNG closed 1.65% below the previous close.
Data tracked by StockTitan Argus for the Aug 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:
Wells Fargo Healthcare Conference
Format: 1x1 meetings
Date: Wednesday, September 9
Location: Boston, MA
Lake Street Best Ideas Growth (BIG10) Conference
Format: 1x1 meetings
Date: Thursday, September 10
Location: New York, NY
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX® Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr® Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, LungTraX®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston or Webb Campbell
Gilmartin Group
investors@pulmonx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.